{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:51Z","timestamp":1786982751603,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40261-024-01363-1","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T16:24:28Z","timestamp":1716654268000},"page":"399-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom"],"prefix":"10.1007","volume":"44","author":[{"given":"Pablo E.","family":"Bretos-Azcona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murvin","family":"Jootun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ion","family":"Agirrezabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agota","family":"Szende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"issue":"6","key":"1363_CR1","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/MOP.0000000000000422","volume":"28","author":"JL Fraser","year":"2016","unstructured":"Fraser JL, Venditti CP. Methylmalonic and propionic acidemias: clinical management update. Curr Opin Pediatr. 2016;28(6):682\u201393.","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"1363_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ymgme.2018.01.009","volume":"123","author":"A Imbard","year":"2018","unstructured":"Imbard A, Garcia Segarra N, Tardieu M, et al. Long-term liver disease in methylmalonic and propionic acidemias. Mol Genet Metab. 2018;123(4):433\u201340.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1363_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ajmg.c.30090","volume":"142c","author":"F Deodato","year":"2006","unstructured":"Deodato F, Boenzi S, Santorelli FM, et al. Methylmalonic and propionic aciduria. Am J Med Genet C Semin Med Genet. 2006;142c(2):104\u201312.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"15","key":"1363_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1056\/NEJM198304143081501","volume":"308","author":"SM Matsui","year":"1983","unstructured":"Matsui SM, Mahoney MJ, Rosenberg LE. The natural history of the inherited methylmalonic acidemias. N Engl J Med. 1983;308(15):857\u201361.","journal-title":"N Engl J Med"},{"issue":"2","key":"1363_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1203\/PDR.0b013e3180a0325f","volume":"62","author":"F H\u00f6rster","year":"2007","unstructured":"H\u00f6rster F, Baumgartner MR, Viardot C, et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut\u2212, cblA, cblB). Pediatr Res. 2007;62(2):225\u201330.","journal-title":"Pediatr Res"},{"issue":"6","key":"1363_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions\u2014a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value in Health. 2015;18(6):906\u201314.","journal-title":"Value in Health."},{"issue":"9","key":"1363_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13023-014-0130-8","volume":"2","author":"MR Baumgartner","year":"2014","unstructured":"Baumgartner MR, H\u00f6rster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;2(9):130.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ebiom.2019.07.003","volume":"45","author":"D An","year":"2019","unstructured":"An D, Frassetto A, Jacquinet E, et al. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. EBioMedicine. 2019;45:519\u201328.","journal-title":"EBioMedicine"},{"issue":"1","key":"1363_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13023-018-0963-7","volume":"13","author":"J H\u00e4berle","year":"2018","unstructured":"H\u00e4berle J, Chakrapani A, Ah Mew N, et al. Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories. Orphanet J Rare Dis. 2018;13(1):219\u2013219.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1363_CR10","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/lt.25304","volume":"24","author":"K Critelli","year":"2018","unstructured":"Critelli K, McKiernan P, Vockley J, et al. Liver transplantation for propionic acidemia and methylmalonic acidemia: perioperative management and clinical outcomes. Liver Transplant. 2018;24(9):1260\u201370.","journal-title":"Liver Transplant"},{"issue":"6","key":"1363_CR11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jpeds.2015.01.051","volume":"166","author":"AK Niemi","year":"2015","unstructured":"Niemi AK, Kim IK, Krueger CE, et al. Treatment of methylmalonic acidemia by liver or combined liver-kidney transplantation. J Pediatr. 2015;166(6):1455-61.e1.","journal-title":"J Pediatr"},{"key":"1363_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ebiom.2019.07.064","volume":"46","author":"J Zimak","year":"2019","unstructured":"Zimak J, Shang Y, Zhao W. mRNA rescues neonatal acidemia while mice report no aftereffects. EBioMedicine. 2019;46:23\u20134.","journal-title":"EBioMedicine"},{"issue":"1","key":"1363_CR13","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","volume":"11","author":"L Jiang","year":"2020","unstructured":"Jiang L, Park JS, Yin L, et al. Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat Commun. 2020;11(1):5339.","journal-title":"Nat Commun"},{"issue":"7","key":"1363_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","volume":"68","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Martini PGV, Avila MA, et al. Messenger RNA therapy for rare genetic metabolic diseases. Gut. 2019;68(7):1323\u201330.","journal-title":"Gut"},{"key":"1363_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.omtm.2022.09.001","volume":"27","author":"RJ Chandler","year":"2022","unstructured":"Chandler RJ, Di Pasquale G, Sloan JL, et al. Systemic gene therapy for methylmalonic acidemia using the novel adeno-associated viral vector 44.9. MolTherapy Methods Clin Dev. 2022;27:61\u201372.","journal-title":"MolTherapy Methods Clin Dev"},{"issue":"12","key":"1363_CR16","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","volume":"21","author":"D An","year":"2017","unstructured":"An D, Schneller JL, Frassetto A, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21(12):3548\u201358.","journal-title":"Cell Rep"},{"key":"1363_CR17","unstructured":"Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease (Press Release). Moderna, Inc. September 2023. Available at: https:\/\/investors.modernatx.com\/news\/news-details\/2023. Accessed Jan 2024. 2023."},{"key":"1363_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","volume":"159","author":"D Witzigmann","year":"2020","unstructured":"Witzigmann D, Kulkarni JA, Leung J, et al. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliv Rev. 2020;159:344\u201363.","journal-title":"Adv Drug Deliv Rev"},{"key":"1363_CR19","unstructured":"Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Available at: http:\/\/www.medicinescomplete.com. Accessed 25 Jan 2024."},{"key":"1363_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). Changes to NICE drug appraisals: what you need to know. Available at: https:\/\/www.nice.org.uk\/news\/feature\/changes-to-nice-drug-appraisals-what-you-need-to-know. Accessed 2 Apr 2021."},{"key":"1363_CR21","unstructured":"National Cost Collection for the NHS. National Schedule of NHS Costs 2018\/19. Available at: https:\/\/www.england.nhs.uk\/national-cost-collection\/. Accessed 7 April 2020."},{"key":"1363_CR22","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available at: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case. Accessed 7 April 2020."},{"issue":"9","key":"1363_CR23","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/lt.24173","volume":"21","author":"M Li","year":"2015","unstructured":"Li M, Dick A, Montenovo M, et al. Cost-effectiveness of liver transplantation in methylmalonic and propionic acidemias. Liver Transplant. 2015;21(9):1208\u201318.","journal-title":"Liver Transplant"},{"issue":"1","key":"1363_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/lt.23765","volume":"20","author":"ER Perito","year":"2014","unstructured":"Perito ER, Rhee S, Roberts JP, et al. Pediatric liver transplantation for urea cycle disorders and organic acidemias: United Network for Organ Sharing data for 2002\u20132012. Liver Transplant. 2014;20(1):89\u201399.","journal-title":"Liver Transplant"},{"issue":"12","key":"1363_CR25","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/lt.25344","volume":"24","author":"J Quintero","year":"2018","unstructured":"Quintero J, Molera C, Juamperez J, et al. the role of liver transplantation in propionic acidemia. Liver Transplant. 2018;24(12):1736\u201345.","journal-title":"Liver Transplant"},{"issue":"1","key":"1363_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13023-019-1045-1","volume":"14","author":"TH Chu","year":"2019","unstructured":"Chu TH, Chien YH, Lin HY, et al. Methylmalonic acidemia\/propionic acidemia - the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups. Orphanet J Rare Dis. 2019;14(1):73.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1363_CR27","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s10897-015-9921-x","volume":"25","author":"K Splinter","year":"2016","unstructured":"Splinter K, Niemi AK, Cox R, et al. impaired health-related quality of life in children and families affected by methylmalonic acidemia. J Genet Couns. 2016;25(5):936\u201344.","journal-title":"J Genet Couns"},{"issue":"4","key":"1363_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ymgme.2014.01.006","volume":"111","author":"G Mazariegos","year":"2014","unstructured":"Mazariegos G, Shneider B, Burton B, et al. Liver transplantation for pediatric metabolic disease. Mol Genet Metab. 2014;111(4):418\u201327.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1363_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10545-005-7056-1","volume":"28","author":"HO de Baulny","year":"2005","unstructured":"de Baulny HO, Benoist JF, Rigal O, et al. Methylmalonic and propionic acidaemias: management and outcome. J Inherit Metab Dis. 2005;28(3):415\u201323.","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"1363_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1750-1172-8-6","volume":"10","author":"SC Gr\u00fcnert","year":"2013","unstructured":"Gr\u00fcnert SC, M\u00fcllerleile S, De Silva L, et al. Propionic acidemia: clinical course and outcome in 55 pediatric and adolescent patients. Orphanet J Rare Dis. 2013;10(8):6.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1363_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ymgme.2011.09.026","volume":"105","author":"KA Chapman","year":"2012","unstructured":"Chapman KA, Gropman A, MacLeod E, et al. Acute management of propionic acidemia. Mol Genet Metab. 2012;105(1):16\u201325.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1363_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10545-011-9426-1","volume":"35","author":"T Zwickler","year":"2012","unstructured":"Zwickler T, Haege G, Riderer A, et al. Metabolic decompensation in methylmalonic aciduria: which biochemical parameters are discriminative? J Inherit Metab Dis. 2012;35(5):797\u2013806.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"1363_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ymgme.2013.05.018","volume":"109","author":"M Abacan","year":"2013","unstructured":"Abacan M, Boneh A. Use of carglumic acid in the treatment of hyperammonaemia during metabolic decompensation of patients with propionic acidaemia. Mol Genet Metab. 2013;109(4):397\u2013401.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"1363_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12887-019-1571-y","volume":"19","author":"M Nashabat","year":"2019","unstructured":"Nashabat M, Obaid A, Al Mutairi F, et al. Evaluation of long-term effectiveness of the use of carglumic acid in patients with propionic acidemia (PA) or methylmalonic acidemia (MMA): study protocol for a randomized controlled trial. BMC Pediatr. 2019;19(1):195.","journal-title":"BMC Pediatr"},{"issue":"2","key":"1363_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10545-005-5260-7","volume":"28","author":"B Gebhardt","year":"2005","unstructured":"Gebhardt B, Dittrich S, Parbel S, et al. N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. J Inherit Metab Dis. 2005;28(2):241\u20134.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"1363_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ymgme.2019.02.007","volume":"126","author":"E Jurecki","year":"2019","unstructured":"Jurecki E, Ueda K, Frazier D, et al. Nutrition management guideline for propionic acidemia: an evidence- and consensus-based approach. Mol Genet Metab. 2019;126(4):341\u201354.","journal-title":"Mol Genet Metab"},{"issue":"2\u20133","key":"1363_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s10545-006-0351-7","volume":"29","author":"G Touati","year":"2006","unstructured":"Touati G, Valayannopoulos V, Mention K, et al. Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture. J Inherit Metab Dis. 2006;29(2\u20133):288\u201398.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"1363_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymgme.2012.07.005","volume":"107","author":"KM Camp","year":"2012","unstructured":"Camp KM, Lloyd-Puryear MA, Huntington KL. Nutritional treatment for inborn errors of metabolism: indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example. Mol Genet Metab. 2012;107(1\u20132):3\u20139.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"1363_CR39","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10545-015-9839-3","volume":"38","author":"S K\u00f6lker","year":"2015","unstructured":"K\u00f6lker S, Garcia-Cazorla A, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015;38(6):1041\u201357.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"1363_CR40","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10545-015-9840-x","volume":"38","author":"S K\u00f6lker","year":"2015","unstructured":"K\u00f6lker S, Valayannopoulos V, Burlina AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis. 2015;38(6):1059\u201374.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"1363_CR41","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jpeds.2015.03.026","volume":"166","author":"JL Sloan","year":"2015","unstructured":"Sloan JL, Manoli I, Venditti CP. Liver or combined liver-kidney transplantation for patients with isolated methylmalonic acidemia: who and when? J Pediatr. 2015;166(6):1346\u201350.","journal-title":"J Pediatr"},{"issue":"8","key":"1363_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134782","volume":"10","author":"K Thiboonboon","year":"2015","unstructured":"Thiboonboon K, Leelahavarong P, Wattanasirichaigoon D, et al. An economic evaluation of neonatal screening for inborn errors of metabolism using tandem mass spectrometry in Thailand. PLoS ONE. 2015;10(8): e0134782.","journal-title":"PLoS ONE"},{"key":"1363_CR43","unstructured":"National Institute for Health and Care Excellence (NICE) health technology evaluations: the manual. Processes and methods [PMG36]. Available at: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/committee-recommendations. Accessed 4 Apr 2024."},{"issue":"62","key":"1363_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20620","volume":"20","author":"T Jones-Hughes","year":"2016","unstructured":"Jones-Hughes T, Snowsill T, Haasova M, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess. 2016;20(62):1\u2013594.","journal-title":"Health Technol Assess"},{"issue":"5\u20136","key":"1363_CR45","first-page":"497","volume":"26","author":"M Rafique","year":"2013","unstructured":"Rafique M. Propionic acidaemia: demographic characteristics and complications. J Pediatr Endocrinol Metab. 2013;26(5\u20136):497\u2013501.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"1363_CR46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1432-2277.2004.00067.x","volume":"18","author":"J Richards","year":"2005","unstructured":"Richards J, Gunson B, Johnson J, et al. Weight gain and obesity after liver transplantation. Transpl Int. 2005;18(4):461\u20136.","journal-title":"Transpl Int"},{"key":"1363_CR47","unstructured":"Department of Health. Reference Costs 2017-18. 2018. Available at:\u00a0https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20200501111106\/https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. Accessed 25 Jan 2024."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01363-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01363-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01363-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:24:24Z","timestamp":1748939064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01363-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01363-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"25 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this study was provided by Fortrea Development Limited (previously Covance Inc. and Labcorp Drug Development).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AS, MAW and GJ are employees of Fortrea Development Limited. PEB, MJ and IA were employees of Fortrea Development Limited during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict\u00a0of Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data used in this analysis were taken from published or publicly available sources.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code\u00a0Availability"}},{"value":"AS, IA, PEB and MJ conceptualized the model. PEB, IA and MJ developed the initial model. AS, MAW and GJ adapted the model. All authors contributed to results interpretation and writing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}